Sagespring Wealth Partners LLC bought a new position in MetLife, Inc. (NYSE:MET - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,332 shares of the financial services provider's stock, valued at approximately $437,000.
Other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC bought a new position in shares of MetLife in the fourth quarter valued at approximately $32,000. Sierra Ocean LLC bought a new stake in shares of MetLife during the fourth quarter valued at approximately $32,000. Graney & King LLC acquired a new position in shares of MetLife in the 4th quarter valued at $34,000. Values First Advisors Inc. bought a new position in shares of MetLife during the 4th quarter worth about $36,000. Finally, Golden State Wealth Management LLC acquired a new stake in shares of MetLife during the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 94.99% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Barclays reduced their target price on shares of MetLife from $95.00 to $88.00 and set an "overweight" rating on the stock in a research note on Friday, April 11th. UBS Group boosted their price target on shares of MetLife from $94.00 to $98.00 and gave the company a "buy" rating in a report on Wednesday, April 2nd. BMO Capital Markets began coverage on shares of MetLife in a research note on Thursday, January 23rd. They issued a "market perform" rating and a $97.00 price target on the stock. Piper Sandler upped their price objective on MetLife from $92.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday, April 2nd. Finally, Morgan Stanley dropped their price objective on MetLife from $109.00 to $94.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $92.46.
Check Out Our Latest Report on MET
MetLife Price Performance
Shares of MetLife stock traded up $0.79 on Friday, hitting $72.49. The company's stock had a trading volume of 2,739,216 shares, compared to its average volume of 3,407,125. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.16 and a current ratio of 0.16. MetLife, Inc. has a 1 year low of $65.21 and a 1 year high of $89.05. The firm has a fifty day moving average price of $79.19 and a 200-day moving average price of $82.12. The company has a market capitalization of $49.38 billion, a price-to-earnings ratio of 12.14, a price-to-earnings-growth ratio of 0.65 and a beta of 0.89.
MetLife (NYSE:MET - Get Free Report) last released its earnings results on Wednesday, February 5th. The financial services provider reported $2.08 EPS for the quarter, missing analysts' consensus estimates of $2.13 by ($0.05). MetLife had a return on equity of 20.42% and a net margin of 6.19%. As a group, sell-side analysts anticipate that MetLife, Inc. will post 9.65 earnings per share for the current fiscal year.
About MetLife
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Further Reading

Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.